01612 VINCENT MED
- 0.470
- 0.0000.00%
VINCENT MED News
Vincent Medical Holdings Limited (HKG:1612) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Vincent Medical Holdings Limited (HKG:1612) shares have had a really impressive month, gaining 27% after a shaky period beforehand. Notwithstanding the latest gain, the annual share price return of
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
永勝醫療：2023年年報
Earnings Beat: Vincent Medical Holdings Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for Vincent Medical Holdings Limited (HKG:1612) shareholders, because the company has just released its latest yearly results, and the shares gained 5.3% to HK$0.40. Result
Vincent Medical Swings to Profit in 2023 as Revenue Jumps 14%
Vincent Medical Holdings (HKG:1612) reported a consolidated attributable net profit of HK$57.3 million for 2023, as opposed to a loss of HK$17.4 million in the preceding year, according to a filing wi
VINCENT MED To Go Ex-Dividend On May 28th, 2024 With 0.015 HKD Dividend Per Share
March 21st - $VINCENT MED(01612.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.015 HKD dividend per share on June 21st, 2024. The ex-dividen
Yongsheng Medical (01612) will pay a final dividend of HK$0.015 per share on June 21
According to the Zhitong Finance App, Yongsheng Healthcare (01612) announced that it will pay a final dividend of HK$0.015 per share for the year ended 31 December 2023 on June 21, 2024.
Yongsheng Medical (01612.HK) turned an annual loss into a profit of HK$57.3 million with a final interest of HK1.5 cents
On March 20, GLONGHUI | Yongsheng Medical (01612.HK) announced that for the year ended December 31, 2023, the company's revenue achieved a steady organic increase of 14.1% to HK$718.0 million. Among them, the disposable imaging products segment increased by 20.0% and the respiratory products segment by 9.6%. The Group turned a loss into a profit in 2023. The consolidated net loss attributable to the owners of the company was HK$17.4 million for the year ended 31 December 2022, reversing the loss and recording a comprehensive profit of HK$57.3 million attributable to the company owner in the current year. Although the new integrated production facility is expected to generate capital
永勝醫療：截至2023年12月31日止年度之全年業績公告、建議宣派末期股息及暫停辦理股份過戶登記手續
Yongsheng Medical (01612.HK) plans to hold a board meeting on March 20 to approve annual results
Gelonghui, March 5, 丨 Yongsheng Medical (01612.HK) announced that the company will hold a board meeting on March 20, 2024 (Wednesday) to consider and approve the final results of the company and its subsidiaries for the year ended 31 December 2023, publish relevant final results, and pay a final dividend (if any).
VINCENT MED: DATE OF BOARD MEETING
Vincent Medical Forecasts Swing to 2023 Profit
Vincent Medical Holdings (HKG:1612) expects an attributable profit of at least HK$52 million for the year ended Dec. 31, 2023, as compared to an attributable loss of HK$17.4 million in 2022. The medic
Yongsheng Medical (01612.HK) Yingxi: Expected annual net profit of not less than HK$52 million
Gelonghui, January 26, 丨 Yongsheng Medical (01612.HK) announced that for the year ended December 31, 2023, the Group expects to record a comprehensive profit of not less than HK$52 million for the year ended 31 December 2023, while for the year ended 31 December 2022, a comprehensive loss attributable to the owners of the audited company was approximately HK$17.4 million.
VINCENT MED: POSITIVE PROFIT ALERT
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Yongsheng Medical (01612.HK) was increased by 170,000 shares by Chairman and Executive Director Cai Wencheng
Glonghui, December 29丨According to the latest equity disclosure data of the Stock Exchange, on December 27, 2023, Yongsheng Medical (01612.HK) was granted an increase of 170,000 shares by Chairman and Executive Director Cai Wencheng at an average price of HK$0.4012 per share on the market, involving approximately HK$68,200. After the increase in holdings, Cai Wencheng's latest shareholding was 393,189,890 shares, and the shareholding ratio increased from 60.16% to 60.18%.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Vincent Medical's Unit to Build 153 Million Yuan Production Facility
Vincent Medical Holdings' (HKG:1612) unit, Guangdong Vincent Medical Technology, plans to construct an integrated production facility for 153 million yuan. The facility, which will have a construction
Analysis
Price Target
No Data
